Markets Stifel cuts CymaBay to hold; PT to $4 from $14 Stifel downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “hold” from “buy” and slashed its price target to $4 from $14 after the company halted development of its sole value driver, seladelpar. The stock closed at $5.55... November 25, 2019